Summary of patient data, CNI, and mTORi
| Age range . | 1-21 y (median, 9.5 y) . |
|---|---|
| Sex, n (%) | |
| Male | 10 (55.6) |
| Female | 8 (44.4) |
| Race/ethnicity, n (%) | |
| White | 8 (44.4) |
| African American | 5 (27.8) |
| Hispanic | 4 (22.2) |
| Asian | 1 (5.6) |
| Allograft, n (%) | |
| Heart | 12 (66.7) |
| Liver | 4 (22.2) |
| Kidney | 1 (5.6) |
| Heart/kidney | 1 (5.6) |
| Immunosuppression, n (%) | |
| CNI | 13 (72.2) |
| mTORi | 4 (22.2) |
| Other | 1 (5.6) |
| Time from transplant to protocol enrollment, n (%) | |
| < 24 mo | 14 (77.8) |
| >24 mo | 4 (22.2) |
| Disease status | |
| ND | 12 (66.7) |
| Relapsed | 1 (5.6) |
| Refractory | 5 (27.8) |
| Pathology, n (%) | |
| Polymorphic | 3 (15.7) |
| Monomorphic | 14 (73.7) |
| Both polymorphic and monomorphic features | 2 (10.5) |
| Age range . | 1-21 y (median, 9.5 y) . |
|---|---|
| Sex, n (%) | |
| Male | 10 (55.6) |
| Female | 8 (44.4) |
| Race/ethnicity, n (%) | |
| White | 8 (44.4) |
| African American | 5 (27.8) |
| Hispanic | 4 (22.2) |
| Asian | 1 (5.6) |
| Allograft, n (%) | |
| Heart | 12 (66.7) |
| Liver | 4 (22.2) |
| Kidney | 1 (5.6) |
| Heart/kidney | 1 (5.6) |
| Immunosuppression, n (%) | |
| CNI | 13 (72.2) |
| mTORi | 4 (22.2) |
| Other | 1 (5.6) |
| Time from transplant to protocol enrollment, n (%) | |
| < 24 mo | 14 (77.8) |
| >24 mo | 4 (22.2) |
| Disease status | |
| ND | 12 (66.7) |
| Relapsed | 1 (5.6) |
| Refractory | 5 (27.8) |
| Pathology, n (%) | |
| Polymorphic | 3 (15.7) |
| Monomorphic | 14 (73.7) |
| Both polymorphic and monomorphic features | 2 (10.5) |
CNI, calcineurin inhibitor; mTORi, mTOR inhibitor.